Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb randomized double-blind double-dummy multicenter study of SIPI6398 in acute schizophrenia
CTR20253241Phase 2Active
- Sponsor
- Zhongze Therapeutics
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ZZ6398 in schizophrenia, sponsored by Zhongze Therapeutics. Started Oct 2025; status: active.
02
Drugs
ZZ6398
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20253241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253241.